Niagen Bioscience (NAGE) Investor presentation summary

Business highlights and market position

• Recognized as a global authority on NAD+ with a significant market opportunity in human and pet nutrition, IV/injectables, cosmetics, and pharmaceuticals.

• Holds over 100 patents and a strong intellectual property portfolio for Niagen and other NAD+ precursors.

• Strategic partnerships with blue chip companies and diversified revenue streams across ecommerce, distribution, and ingredient sales.

• Independent scientific research supports a broad clinical pipeline, especially in Ataxia and Parkinson's disease.

• NAD+ and anti-aging supplements are gaining mainstream attention, endorsed by celebrities and athletes.

Financial performance and outlook

• Q3 2025 LTM revenues reached $124.7m, with $20.4m net income and $64.3m in cash, no debt.

• Gross margin improved to 65% in Q3 2025, driven by new verticals and supply chain efficiencies.

• Adjusted EBITDA rose to $6.4m in Q3 2025, with profitability and a strong balance sheet supporting future investments.

• 2025 net sales expected to grow 25–30% YoY, supported by ecommerce, B2B partnerships, and supply chain optimization.

• Strategic investments planned in brand building, R&D, and marketing to drive innovation and expansion.

Product portfolio and innovation

• Core consumer health verticals led by Niagen and Tru Niagen brands, with strong growth and expansion into healthy aging markets.

• Launched Niagen Plus for IV and injectables, targeting the $100m NAD+ IV market with pharmaceutical-grade products.

• Niagen IV offers faster infusion, minimal side effects, and higher NAD+ levels compared to traditional NAD+ IV.

• Over 1,000 clinics onboarded for Niagen IV since August 2024, generating $4.6m in ingredient sales.

• Proprietary NAD+ test kit enables precise measurement and personalized protocols for patients.